An open-label, randomized, phase 1b study evaluating the effect of different doses of AMG 706 [motesanib] on the gallbladder in subjects with advanced solid tumors.
Phase of Trial: Phase I
Latest Information Update: 07 Jun 2011
At a glance
- Drugs Motesanib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Amgen
- 07 Jun 2011 Results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
- 18 Aug 2009 Actual end date (1 Mar 2009) added as reported by ClinicalTrials.gov.
- 18 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.